Significance of Laboratory Examination in The Diagnosis of Ulcerative Colitis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 KUAIGuo-hu ¹ ,  LIChun-yu ²

1. Department of Neurosurgery, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan 430064, Hubei Province, China;
2. Department of Colorectal Surgery, The Forth Hospital, China Medical University, Shenyang 110032, Liaoning Province, China;

Corresponding?author：

LIChun-yu, Email: lcy133000@163.com

Keywords：

Ulcerative colitis; Diagnosis; Non-invasive examination; Laboratory examination

DOI：

10.7507/1007-9424.20140093

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the significance of laboratory examinations in diagnosis of ulcerative colitis (UC). Methods Literatures at home and abroad were searched to review the clinical significance of laboratory examinations indexes in diagnosis of UC. Results Anti-neutrophilcytoplasmicantibodies (ANCA) had some value in diagnosis of UC, but it was limited in evaluation of UC in active patients. The positive rate of anti-intestinal goblet cell antibody (GAB) in patients with UC was higher than that of patients with Crohn's disease (CD), so it could be used as identification indexes of the two diseases, but it could not reflect the severity of the disease. Anti-saccharomyces cerevisiae antibodies (ASCA) and anti-pancreatic antibody (PAB) were mainly used in the differential diagnosis of UC and CD, but they had no significant advantages in diagnosis of UC. Fecal calprotectin (FCP) played a positive role in evaluation of recurrence and activity in UC. Although lactoferrin, M2-pyruvate kinase (M2-PK), and S100A12 were not as effective as FCP, but if combined with related indicators, they were also important. Conclusions Of the relevant indexes of laboratory examination in the diagnosis of UC, FCP plays an importent role in the evaluation of recurrence and activity of UC.

Citation： KUAIGuo-hu, LIChun-yu. Significance of Laboratory Examination in The Diagnosis of Ulcerative Colitis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(3): 383-387. doi: 10.7507/1007-9424.20140093 Copy

1.	?李艷萍. 867例抗中性粒細胞胞漿抗體檢測的臨床分析[J].吉林醫學, 2012, 33(11):2265-2266.
2.	吳登峰, 王承黨.福建省潰瘍性結腸炎住院患者病情回顧分析[J].胃腸病學和肝病學雜志, 2010, 19(7):639-642.
3.	邱麗.檢測核周型抗中性粒細胞胞漿抗體在潰瘍性結腸炎中的意義[J].浙江臨床醫學, 2012, 14(12):1471-1472.
4.	王瓊, 楊曉鐘, 馬剛.自身抗體及相關抗原檢測對炎癥性腸病患者的臨床意義研究[J].齊齊哈爾醫學院學報, 2010, 31(23):3709-3711.
5.	邱潔英, 劉光金, 楊小金.實驗室檢測對潰瘍性結腸炎患者診斷和評估預后的相關研究[J].實驗與檢驗醫學, 2010, 28(2):153-154, 158.
6.	Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients[J]. Am J Gastroenterol, 2004, 99(11):2186-2194.
7.	Oudkerk Pool M, Bouma G, Meuwissen SG, et al. Serological markers to differentiate between ulcerative colitis and Crohn's disease[J]. J Clin Pathol, 1995, 48(4):346-350.
8.	范如英, 武子濤, 盛劍秋.核周型抗中性粒細胞胞漿抗體在潰瘍性結腸炎診斷中的意義[J].胃腸病學和肝病學雜志, 2012, 21(8):758-759.
9.	楊冬, 王貞.炎癥性腸病血清相關抗體檢測的臨床價值[J].大連醫科大學學報, 2010, 32(3):343-347.
10.	何淳, 張蜀瀾, 李永哲, 等.炎癥性腸病患者中四種自身抗體聯合檢測的臨床意義[J].標記免疫分析與臨床, 2008, 15(5):268-271.
11.	Lawrance IC, Hall A, Leong R, et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD[J]. Inflamm Bowel Dis, 2005, 11(10):890-897.
12.	Kuna AT. Serological markers of inflammatory bowel disease[J]. Biochem Med (Zagreb), 2013, 23(1):28-42.
13.	Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2012, 55(4):429-435.
14.	王志紅, 趙曉軍, 韓英.抗中性粒細胞胞質抗體和抗釀酒酵母抗體表達在炎癥性腸病診斷中的意義[J].解放軍醫學雜志, 2008, 33(10):1244-1245.
15.	Saibeni S, Folli C, de Franchis R, et al. Diagnostic role and clinical correlates of anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases[J]. Dig Liver Dis, 2003, 35(12):862-868.
16.	Kili? ZM, Tun? B, Ayaz S, et al. Antineutrophil cytoplasmic autoantibodies and anti-saccharomyces cerevisiae antibodies in inflammatory bowel diseases[J]. Turk J Gastroenterol, 2004, 15(4):238-242.
17.	Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives[J]. World J Gastroenterol, 2010, 16(45):5732-5738.
18.	Homsak E, Miceti?-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease:prevalence, charac-teristics and diagnostic value[J]. Wien Klin Wochenschr, 2010, 122 Suppl 2:19-25.
19.	Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells[J]. Bull Eur Physiopathol Respir, 1980, 16 Suppl:273-282.
20.	Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macro-phage subset in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes[J]. Gut, 1994, 35(5):669-674.
21.	R?seth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein[J]. Digestion, 1997, 58(2):176-180.
22.	Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease[J]. Dig Liver Dis, 2009, 41(1):56-66.
23.	沈姞, 李俊霞, 王化虹, 等.糞便鈣衛蛋白對潰瘍性結腸炎的診斷及預測復發的價值[J].腸外與腸內營養, 2011, 18(5):272-276.
24.	Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes[J]. Inflamm Bowel Dis, 2013, 19(2):332-341.
25.	Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis[J]. Inflamm Bowel Dis, 2013, 19(5):1034-1042.
26.	Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases:a meta-analysis of pros-pective studies[J]. Inflamm Bowel Dis, 2012, 18(10):1894-1899.
27.	張穎, 王英德.糞便鈣衛蛋白、抗中性粒細胞胞漿抗體檢測在潰瘍性結腸炎診斷中的價值比較[J].中華臨床醫師雜志:電子版, 2012, 6(6):1620-1622.
28.	王少東, 施惠, 陸恒, 等.糞便鈣衛蛋白在全消化系統疾病鑒別診斷中的意義[J].胃腸病學, 2012, 17(4):237-239.
29.	Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin:correlation with laboratory parameters, clinical, endoscopic and histological indexes[J]. BMC Res Notes, 2009, 2:221.
30.	Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse[J]. Inflamm Bowel Dis, 2009, 15(8):1190-1198.
31.	向軍英, 歐陽欽, 李國棟.糞便乳鐵蛋白在評價潰瘍性結腸炎活動性中的價值[J].中華醫學雜志, 2007, 87(32):2262-2264.
32.	Fahlgren A, Hammarstr?m S, Danielsson A, et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis[J]. Clin Exp Immunol, 2003, 131(1):90-101.
33.	Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis:a prospective multicentre comparison of predicting outcomes and monitoring response[J]. Gut, 2010, 59(9):1207-1212.
34.	Johnson MW, Maestranzi S, Duffy AM, et al. Faecal M2-pyruvate kinase:a novel, noninvasive marker of ileal pouch inflammation[J]. Eur J Gastroenterol Hepatol, 2009, 21(5):544-550.
35.	Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK):a novel marker of intestinal inflammation[J]. Inflamm Bowel Dis, 2007, 13(11):1374-1378.
36.	D?britz J, Langhorst J, Lügering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12[J]. Inflamm Bowel Dis, 2013, 19(6):1130-1138.
37.	Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome[J]. Gut, 2007, 56(12):1706-1713.

1. ?李艷萍. 867例抗中性粒細胞胞漿抗體檢測的臨床分析[J].吉林醫學, 2012, 33(11):2265-2266.
2. 吳登峰, 王承黨.福建省潰瘍性結腸炎住院患者病情回顧分析[J].胃腸病學和肝病學雜志, 2010, 19(7):639-642.
3. 邱麗.檢測核周型抗中性粒細胞胞漿抗體在潰瘍性結腸炎中的意義[J].浙江臨床醫學, 2012, 14(12):1471-1472.
4. 王瓊, 楊曉鐘, 馬剛.自身抗體及相關抗原檢測對炎癥性腸病患者的臨床意義研究[J].齊齊哈爾醫學院學報, 2010, 31(23):3709-3711.
5. 邱潔英, 劉光金, 楊小金.實驗室檢測對潰瘍性結腸炎患者診斷和評估預后的相關研究[J].實驗與檢驗醫學, 2010, 28(2):153-154, 158.
6. Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients[J]. Am J Gastroenterol, 2004, 99(11):2186-2194.
7. Oudkerk Pool M, Bouma G, Meuwissen SG, et al. Serological markers to differentiate between ulcerative colitis and Crohn's disease[J]. J Clin Pathol, 1995, 48(4):346-350.
8. 范如英, 武子濤, 盛劍秋.核周型抗中性粒細胞胞漿抗體在潰瘍性結腸炎診斷中的意義[J].胃腸病學和肝病學雜志, 2012, 21(8):758-759.
9. 楊冬, 王貞.炎癥性腸病血清相關抗體檢測的臨床價值[J].大連醫科大學學報, 2010, 32(3):343-347.
10. 何淳, 張蜀瀾, 李永哲, 等.炎癥性腸病患者中四種自身抗體聯合檢測的臨床意義[J].標記免疫分析與臨床, 2008, 15(5):268-271.
11. Lawrance IC, Hall A, Leong R, et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD[J]. Inflamm Bowel Dis, 2005, 11(10):890-897.
12. Kuna AT. Serological markers of inflammatory bowel disease[J]. Biochem Med (Zagreb), 2013, 23(1):28-42.
13. Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2012, 55(4):429-435.
14. 王志紅, 趙曉軍, 韓英.抗中性粒細胞胞質抗體和抗釀酒酵母抗體表達在炎癥性腸病診斷中的意義[J].解放軍醫學雜志, 2008, 33(10):1244-1245.
15. Saibeni S, Folli C, de Franchis R, et al. Diagnostic role and clinical correlates of anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases[J]. Dig Liver Dis, 2003, 35(12):862-868.
16. Kili? ZM, Tun? B, Ayaz S, et al. Antineutrophil cytoplasmic autoantibodies and anti-saccharomyces cerevisiae antibodies in inflammatory bowel diseases[J]. Turk J Gastroenterol, 2004, 15(4):238-242.
17. Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives[J]. World J Gastroenterol, 2010, 16(45):5732-5738.
18. Homsak E, Miceti?-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease:prevalence, charac-teristics and diagnostic value[J]. Wien Klin Wochenschr, 2010, 122 Suppl 2:19-25.
19. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells[J]. Bull Eur Physiopathol Respir, 1980, 16 Suppl:273-282.
20. Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macro-phage subset in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes[J]. Gut, 1994, 35(5):669-674.
21. R?seth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein[J]. Digestion, 1997, 58(2):176-180.
22. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease[J]. Dig Liver Dis, 2009, 41(1):56-66.
23. 沈姞, 李俊霞, 王化虹, 等.糞便鈣衛蛋白對潰瘍性結腸炎的診斷及預測復發的價值[J].腸外與腸內營養, 2011, 18(5):272-276.
24. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes[J]. Inflamm Bowel Dis, 2013, 19(2):332-341.
25. Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis[J]. Inflamm Bowel Dis, 2013, 19(5):1034-1042.
26. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases:a meta-analysis of pros-pective studies[J]. Inflamm Bowel Dis, 2012, 18(10):1894-1899.
27. 張穎, 王英德.糞便鈣衛蛋白、抗中性粒細胞胞漿抗體檢測在潰瘍性結腸炎診斷中的價值比較[J].中華臨床醫師雜志:電子版, 2012, 6(6):1620-1622.
28. 王少東, 施惠, 陸恒, 等.糞便鈣衛蛋白在全消化系統疾病鑒別診斷中的意義[J].胃腸病學, 2012, 17(4):237-239.
29. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin:correlation with laboratory parameters, clinical, endoscopic and histological indexes[J]. BMC Res Notes, 2009, 2:221.
30. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse[J]. Inflamm Bowel Dis, 2009, 15(8):1190-1198.
31. 向軍英, 歐陽欽, 李國棟.糞便乳鐵蛋白在評價潰瘍性結腸炎活動性中的價值[J].中華醫學雜志, 2007, 87(32):2262-2264.
32. Fahlgren A, Hammarstr?m S, Danielsson A, et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis[J]. Clin Exp Immunol, 2003, 131(1):90-101.
33. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis:a prospective multicentre comparison of predicting outcomes and monitoring response[J]. Gut, 2010, 59(9):1207-1212.
34. Johnson MW, Maestranzi S, Duffy AM, et al. Faecal M2-pyruvate kinase:a novel, noninvasive marker of ileal pouch inflammation[J]. Eur J Gastroenterol Hepatol, 2009, 21(5):544-550.
35. Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK):a novel marker of intestinal inflammation[J]. Inflamm Bowel Dis, 2007, 13(11):1374-1378.
36. D?britz J, Langhorst J, Lügering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12[J]. Inflamm Bowel Dis, 2013, 19(6):1130-1138.
37. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome[J]. Gut, 2007, 56(12):1706-1713.

Previous Article
Science and Ethics in Conducting Cardiothoracic Surgery with Da Vinci Surgical System in China: A Systematic Review
Next Article

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Significance of Laboratory Examination in The Diagnosis of Ulcerative Colitis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content